SCHEMBL7022096

SCHEMBL7022096

CC(C)[Si](C(C)C)(C(C)C)n1ccc2nc(Br)ccc21

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4230103 0.80 PDE10A (0.33) —
SCHEMBL857483 0.74 — —
SCHEMBL31018246 0.73 MAPK1 (0.34) —
SCHEMBL31018247 0.73 MAPK1 (0.34) —
SCHEMBL413823 0.72 HTR2A (0.50) —
SCHEMBL30967900 0.72 HTR2A (0.50) —
SCHEMBL16417124 0.72 PRKCI (0.38) —
SCHEMBL1336229 0.70 HSD17B10 (0.36) —
SCHEMBL516662 0.69 HTR7 (0.40) —
SCHEMBL19617761 0.68 — —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20200231593-A1 SALTS AND CRYSTALLINE FORMS OF AN APOPTOSIS-INDUCING AGENT ABBVIE INC (US) 2020-07-23 — — US disclosed
EP-1089993-B1 5-HT1F AGONISTS LILLY CO ELI (US) 2003-10-22 — — EP disclosed
US-6358972-B1 FOR THERAPY OF MIGRAINE ELI LILLY AND COMPANY 2002-03-19 — — US disclosed
EP-1089993-A1 5-HT1F AGONISTS ELI LILLY AND COMPANY (US) 2001-04-11 — — EP disclosed
WO-2000000490-A2 5-HT1F AGONISTS ELI LILLY AND COMPANY (US) 2000-01-06 — — WO disclosed
WO-2000000487-A1 5-HT1F AGONISTS ELI LILLY AND COMPANY (US) 2000-01-06 — — WO disclosed
Send feedback